NGNE Stock Summary and Trading Ideas (Neurogene | NASDAQ:NGNE)

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Neurogene trades on the NASDAQ stock market under the symbol NGNE.

As of November 13, 2025, NGNE stock price declined to $27.14 with 317,375 million shares trading.

NGNE has a beta of 3.68, meaning it tends to be more sensitive to market movements. NGNE has a correlation of 0.21 to the broad based SPY ETF.

NGNE has a market cap of $387.07 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that NGNE belongs to (by Net Assets): IWM, VTI, IWN, IBB, VXF.

NGNE has underperformed the market in the last year with a price return of -32.2% while the SPY ETF gained +13.7%. However, in the short term, NGNE had mixed performance relative to the market. It has outperformed in the last 3 months, returning +41.2% vs +4.7% return in SPY. But in the last 2 weeks, NGNE shares have been beat by the market, returning -16.9% compared to an SPY return of -2.3%.

NGNE support price is $28.61 and resistance is $33.55 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NGNE shares will trade within this expected range on the day.